Sign In
Buy XLV
$162.55
-0.97 (-0.593%)
At Close: Jul 31, 2026
XLV vs. IBBQ: Is Broad Healthcare Exposure or Biotech Growth the Better ETF Buy?
05:11pm, Saturday, 01'st Aug 2026
The Health Care Select Sector SPDR Fund (XLV) carries a lower expense ratio and a higher dividend yield than the Invesco Nasdaq Biotechnology ETF (IBBQ). IBBQ has significantly outperformed on a one-y
XLV vs PBE: Is a Low-Cost Healthcare ETF the Better Buy Than a Focused Biotech Specialist?
01:57pm, Saturday, 01'st Aug 2026
State Street Health Care Select Sector SPDR ETF offers a significantly lower expense ratio of 0.08% compared to 0.58% for Invesco Biotechnology & Genome ETF Invesco Biotechnology & Genome ETF holds a
XLV vs. IHE: Which Healthcare ETF Is the Better Buy?
11:53am, Friday, 31'st Jul 2026
The Health Care Select Sector SPDR Fund (XLV) carries a significantly lower expense ratio than the iShares U.S. Pharmaceuticals ETF (IHE). IHE concentrates exclusively on the pharmaceutical industry,
Financial Sector ETF Hits Record High on Fintech Gains
01:48pm, Tuesday, 28'th Jul 2026
Shares of the State Street Financial Select Sector SPDR ETF (XLF) touched a fresh all-time high Tuesday. That gain is part of a broader shift in the market.
UnitedHealth Pulls Back Post 52-Week High: Healthcare ETFs to Watch
04:31pm, Monday, 27'th Jul 2026
UNH's post-earnings pullback follows a 52-week high, as stronger guidance offsets Medicaid pressures and spotlights healthcare ETFs with sizable exposure.
XLV vs IYH: Which Healthcare ETF Wins on Cost and Yield?
09:10am, Monday, 27'th Jul 2026
State Street Health Care Select Sector SPDR ETF maintains a significantly lower expense ratio of 0.08% compared to 0.38% for iShares U.S. Healthcare ETF Both funds are heavily concentrated in the heal
XLV vs FHLC: Which Healthcare ETF Fits Your Portfolio?
08:35am, Monday, 27'th Jul 2026
The State Street Health Care Select Sector SPDR ETF manages $41.7 billion in assets under management (AUM), providing significantly higher liquidity than the Fidelity MSCI Health Care Index ETF Fideli
PINK vs. XLV: How Do These Two Health Care ETFs Match Up?
05:40pm, Sunday, 26'th Jul 2026
State Street Health Care Select Sector SPDR ETF has a much lower expense ratio and significantly higher assets under management than Simplify Health Care ETF Simplify Health Care ETF outperformed on a
Is the VanEck Pharmaceutical ETF or State Street Health Care ETF the Better Buy for Your Portfolio?
01:01pm, Sunday, 26'th Jul 2026
The State Street Health Care Select Sector SPDR ETF offers a significantly lower expense ratio and higher assets under management than the VanEck Pharmaceutical ETF VanEck Pharmaceutical ETF focuses e
Healthcare Systems' Liquidity Challenge
08:25am, Saturday, 25'th Jul 2026
Healthcare systems are facing rising operating pressure, thinner margins, and a harder question about how to manage liquidity across the balance sheet as capital needs become more uncertain. Liquidity
Risk-Wary Family Offices Double Down on Infrastructure
03:28pm, Tuesday, 21'st Jul 2026
Geopolitical shocks have pushed family offices to rethink nearly every corner of their portfolios. Infrastructure has emerged as the asset class they trust most right now.
Which Is the Better Healthcare ETF, First Trust's Biotech-Focused FBT or State Street's Broader XLV?
07:57am, Tuesday, 21'st Jul 2026
FBT delivered 52.4% returns over one year but with deeper drawdowns, while XLV's diversified approach offers lower costs and steadier performance.
XLV: Healthcare Sector On The Mend, But Probably Not For Long
08:30am, Saturday, 18'th Jul 2026
The State Street Health Care Select Sector SPDR ETF might be a port in the storm for a while, but its best upside is likely behind it for this cycle. A year 2000-like cycle is hinting again. That's wh
Drug Pipeline Wins State Street Over on Healthcare
05:18pm, Tuesday, 14'th Jul 2026
State Street Investment Management is turning positive on healthcare stocks after nearly a year of caution. The firm's Q3 2026 sector outlook upgraded healthcare from neutral to positive.
Healthcare ETFs to Buy as JNJ Beats the Market With a 25% YTD Surge
10:56am, Tuesday, 14'th Jul 2026
JNJ's 25% year-to-date surge and recent FDA approval fuel interest in healthcare ETFs with diversified sector exposure.
